Latest From Agenus Inc.
Gilead will pay $4.9bn to acquire Forty Seven and its potential first-in-class anti-CD47 agent magrolimab. A fast-track development effort in myelodysplastic syndrome will be the initial focus for that asset.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish
Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- Antigenics Inc.
- North America
- Parent & Subsidiaries
- Agenus Inc.
- Senior Management
Garo H Armen, PhD, Chmn. & CEO
Alex Duncan, PhD, CTO
Julie DeSander, VP, Bus. Dev. & Alliance Mngmt.
Jennifer Buell, PhD, Pres. & COO
Christine Klaskin, VP, Fin.
- Contact Info
Phone: (781) 674-4400
3 Forbes Rd.
Lexington, MA 02421-7305
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.